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Abstract We purified DNase II from human liver to apparent
homogeneity. The N-terminal amino acid sequences of each of
three components constituting the purified mature enzyme were
then separately determined by automatic Edman degradation. A
combination of this chemical information and the previously
reported nucleotide sequence of the cDNA encoding human
DNase II [Yasuda et al. (1998) J. Biol. Chem. 273, 2610^2626]
allowed detailed elucidation of the enzyme’s subunit structure:
human DNase II was composed of three non-identical subunits, a
propeptide, proprotein and mature protein, following a signal
peptide. Expression analysis of a series of deletion mutants
derived from the cDNA of DNase II in COS-7 cells suggested
that although a single large precursor protein may not be
necessary for proteolytic maturation, the propeptide region L17^
Q46 may play an essential role in generating the active form of
the enzyme.
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1. Introduction
Although the physiological role(s) of the ubiquitously dis-
tributed enzyme DNase II (EC 3.1.22.1) has not yet been fully
elucidated [1,2] and it appears to occur primarily in intracel-
lular lysosomes [3], the enzyme is postulated to be involved in
some cases of apoptosis, in which it may play a role in DNA
ladder formation [4]. We have previously demonstrated the
genetic polymorphism of human DNase II with regard to
di¡erences in its activity levels [5]. However, very little infor-
mation on the molecular structure of DNase II has been ob-
tained: chemical properties reported so far have shown great
variability, and even its molecular mass and subunit structure
remain to be con¢rmed [2^4,6]. Recently, we successfully ac-
complished the ¢rst molecular cloning of the cDNA encoding
mammalian (human) DNase II [7], and clari¢ed both its chro-
mosomal localization [8] and its genomic structure [9]. The
composite nucleotide sequence of this cDNA includes an
open reading frame of 1080 bp, which encodes a single poly-
peptide of 360 amino acid residues. These cDNA data led us
to speculate that the translated product consists of three por-
tions, a putative signal peptide, proprotein and mature pro-
tein. However, although our cDNA information allowed de-
tailed elucidation of the structural properties of the enzyme,
chemical approaches, including expression analysis of the re-
combinant proteins in eukaryotic cells, were required to ¢-
nally con¢rm its molecular structure.
In the present paper, we describe the puri¢cation of DNase
II from human liver, the identi¢cation of the three subunits
constituting the enzyme and the expression analysis of the
recombinant proteins in COS-7 cells.
2. Materials and methods
2.1. Analytical methods and materials
DNase II activity was assayed by the single radial enzyme di¡usion
(SRED) method [1]. Protein quantities were determined using a pro-
tein assay kit (Bio-Rad, Richmond, CA) with BSA as a standard. The
conventional method was used to assay L-D-galactosidase [10]. SDS-
PAGE was performed in 15% gels according to the method of
Laemmli [11], and the proteins thus separated were visualized by silver
staining or immunoblotting [12]. A speci¢c antibody against human
DNase II was prepared according to our previously reported method
[1].
2.2. Puri¢cation of DNase II from human liver
A whole human liver was obtained from a 57-year-old woman at
postmortem, 12 h after death due to loss of blood. The liver (ca. 1200
g) was homogenized in 0.1 M sodium phosphate (pH 6.2) containing
10 mM EDTA and 1 mM PMSF. After the homogenate had been
adjusted to pH 2.5 with phosphoric acid and centrifuged at 10 000Ug
for 30 min, the supernatant was subjected to ammonium sulfate frac-
tionation. The fraction precipitated between 0.3 and 0.9 ammonium
sulfate saturation was collected and dialyzed against 50 mM sodium
acetate (pH 4.5) containing 5 mM EDTA and 1 mM PMSF (bu¡er
A). The dialysate was applied to a CM-Sepharose CL-6B column
(2.8U40 cm; Amersham Pharmacia Biotech, Uppsala, Sweden) pre-
equilibrated with bu¡er A, and the adsorbed materials were eluted
with a linear NaCl gradient (0^1.0 M). The fractions showing DNase
II activity were dialyzed against 50 mM sodium acetate (pH 5.0)
containing 5 mM EDTA and 1 mM PMSF (bu¡er B), and applied
to an SE-53 column (2.8U40 cm; Whatman, Maidstone, UK) pre-
equilibrated with bu¡er B. After the active fractions had been dialyzed
against 50 mM sodium acetate (pH 5.0) containing 5 mM EDTA, 3%
(v/v) glycerol and 0.5 mM 2-mercaptoethanol (2ME) (bu¡er C), the
dialysate was applied to a Reactive blue 4-agarose column (1.6U12
cm; Sigma, St. Louis, MO) pre-equilibrated with bu¡er C and eluted
with a linear NaCl gradient (0^1.5 M). The active fractions were
redialyzed against the same bu¡er and applied to a heparin-Actigel
column (1.0U20 cm; Sterogen Biochemicals, San Gabriel, CA) pre-
equilibrated with bu¡er C. The active fractions were eluted with a
linear NaCl gradient (0^1.0 M) and dialyzed against 25 mM potassi-
um phosphate (pH 6.0) containing 5 mM EDTA, 3% (v/v) glycerol
and 0.5 mM 2ME (bu¡er D). The dialysates were applied to a P-11
column (1.0U15 cm; Whatman) pre-equilibrated with bu¡er D, and
eluted with a linear NaCl gradient (0^1.0 M). The active fractions
were ¢nally subjected to gel ¢ltration on a Sephadex G-75 column
(1.6U100 cm; Amersham Pharmacia Biotech) pre-equilibrated with
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bu¡er D supplemented with 0.25 M NaCl. The active fractions were
collected, concentrated and used for the subsequent analysis.
2.3. N-terminal amino acid sequence analysis
After separation of the puri¢ed DNase II (ca. 100 Wg) by SDS-
PAGE on a 15% gel, the resulting proteins were electro-transferred
onto an Immobilon-P membrane (Millipore, Bedford, MA). The por-
tion of the membrane carrying the proteins and the intact DNase II
preparation (ca. 20 Wg) were subjected to automatic Edman degrada-
tion using a protein sequencer (model 494; Perkin-Elmer, Urayasu,
Japan).
2.4. Construction of expression vectors and deletion mutagenesis
A DNA fragment containing all the coding sequences for human
DNase II was obtained by reverse transcriptase (RT)-PCR ampli¢ca-
tion of the total RNA derived from the thyroid gland of a 48-year-old
man, obtained 12 h after death due to loss of blood, using a set of two
primers, DN2-N6 (5P-AAAGGATCCATAGCAGCTATGATCCC-
GCTGCTGCTG-3P) and DN2-C5 (5P-AAAGCGGCCGCTTAGA-
TCTTATAAGCTCTGCTGGG-3P). RT-PCR was performed accord-
ing to a previously described method [7]. The fragment was ligated
into the pcDNA3.1(+) vector (Invitrogen, San Diego, CA) to con-
struct the expression vector pcDNA3.1-DN2. In the same manner,
DNase II cDNA was cloned in its antisense orientation into the
pcDNA3.1 vector to produce the vector pcDNA3.1-DN2anti. A series
of deletion mutants were constructed by RT-PCR using the following
primers, the sequences of which are numbered from the ¢rst ATG.
Forward primers were: DN2-D7, 5P-AAAGGATCCATAGCAGC-
TATGCTGACCTGCTACGGG-3P (49^65 bp), in which the sequence
from position 319 to 3 bp was included; DN2-E4, 5P-AGAG-
GGCTGCAGTACAAGTATC-3P (139^160 bp); and DN2-E2, 5P-
TCTTCCATGCGTGGGCACAC-3P (322^341 bp). Reverse primers
were: DN2-E1, 5P-GCCCACGCATGGAAGAGGCCCCGGGGG-
GAC-3P (34^48 bp), in which the sequence from position 322 to 337
bp was included so as to introduce the juxtaposition of amino acids
A16 and S108 ; DN2-E3, 5P-GTACTGCAGCCCTCTGGCCCCG-
GCGGGGAG-3P (34^48 bp), in which the sequence from position
139 to 160 bp was included so as to introduce the juxtaposition of
amino acids A16 and R47 ; DN2-E5, 5P-AAAGCGGCCGCTTA-
GTCCTGAGCCTTGCTGGG-3P (304^321 bp) and DN2-E6, 5P-
AAAGCGGCCGCTTAACTGCGCCGCCTCCCCGGACC-3P (119^
138 bp), which included the translation termination codon. The dele-
tion mutants vM1^A16 (vS), vS108^I360 (vM) and vR47^I360
(v(P+M)), which lacked part of the signal peptide (S), the mature
protein (M), and the proprotein (P)/M, respectively, were produced
using the following combinations of primers: DN2-D7/C5, DN2-N6/
E5, and DN2-N6/E6, respectively. Splicing by the overlap extension
method [13] was also employed to construct another three deletion
mutants, vL17^D107 (v(PT+P)), vL17^Q46 (vPT) and vL17^Q46/S108^
I360 (v(PT+M)), which lacked part of the propeptide (PT)/P region,
PT and PT/M, respectively. This process used the three primer sets
DN2-N6/E1/E2/C6, DN2-N6/E3/E4/C6 and DN2-N6/E3/E4/E5, re-
spectively. Each ampli¢ed fragment was cloned into the expression
vector pcDNA3.1(+). All the mutants were veri¢ed by restriction
mapping and partial DNA sequencing. Plasmid DNAs for transfec-
tion were puri¢ed using the Plasmid Midi Kit (Qiagen, Chatsworth,
CA).
2.5. Transfection of the expression vectors into COS-7 cells
COS-7 cells were maintained in Dulbecco’s modi¢ed Eagle’s me-
dium containing 1 mM L-glutamine, 50 U/ml penicillin, 50 Wg/ml
streptomycin and 10% (v/v) fetal calf serum (Gibco BRL) at 37‡C
under 5% CO2. The cells were transiently transfected using Lipofec-
taminPlus reagent (Gibco BRL) according to the manufacturer’s in-
structions. Transfection e⁄ciencies were estimated by cotransfecting
with the pSV-L-galactosidase vector (Promega, Madison, WI) and
subsequently assaying aliquots of cell lysates for L-D-galactosidase
activity. Two days after transfection, the medium was recovered and
cell lysates were prepared by performing ¢ve freeze-thaw cycles in
0.25 M Tris-HCl (pH 7.5) containing 1 mM PMSF. DNase II activ-
ities in both the cell lysates and medium were assayed by the SRED
method.
3. Results and discussion
3.1. Puri¢cation of DNase II from human liver
The seven-step puri¢cation procedure resulted in approxi-
mately 2300-fold puri¢cation with a 10% yield, and about 700
Wg DNase II was obtained from the whole human liver (Table
1). Human DNase II has previously been only partially puri-
¢ed from the gastric mucosa, uterine cervix [14], urine [1] and
lymphoblasts [15]. Therefore, this is the ¢rst report of the
puri¢cation of DNase II to apparent homogeneity from a
human source. When the enzyme was subjected to SDS-
PAGE after denaturation by dithiothreitol (DTT) at 100‡C,
only two bands were detected at corresponding positions by
both silver staining and immunostaining (Fig. 1). The molec-
ular masses of these proteins were estimated to be 8^10 kDa
and 32 kDa. However, without denaturation, the puri¢ed en-
zyme yielded only a single 45 kDa band (Fig. 1). These ¢nd-
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Table 1
Puri¢cation of DNase II from human whole liver
Step Protein Total activity Speci¢c activity Puri¢cation Yield
(mg) (units) (units/mg) (fold) (%)
Crude extract 15 300 31 200 2.04 1 100
1. Ammonium sulfate fractionation 1 034 24 500 23.7 11.6 78.5
2. CM-Sepharose CL-6B 234 15 700 67.1 32.9 50.3
3. SE-53 27.4 12 500 456 224 40.1
4. Reactive blue 4-agarose 19.3 11 100 575 282 35.6
5. Heparin-Actigel 7.20 8 750 1220 598 28.0
6. P-11 0.71 3 200 4510 2210 10.3
7. Sephadex G-75 0.69 3 180 4610 2260 10.2
DNase II activity and protein concentration were measured as described in Section 2.
Fig. 1. SDS-PAGE patterns of puri¢ed human DNase II, with and
without DTT treatment. The puri¢ed enzyme (about 5 Wg, lanes 1
and 2; 2 Wg, lanes 3 and 4) was either heated to 100‡C in the pres-
ence of 25 mM DTT (lanes 1 and 3) or not exposed to heat/DTT
(lanes 2 and 4), and was then subjected to SDS-PAGE on a 15%
gel according to the method of Laemmli [11]. Afterwards, the pro-
teins were visualized by silver staining (lanes 1 and 2) or immuno-
staining with anti-human DNase II (lanes 3 and 4).
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ings suggest that human DNase II is composed of non-iden-
tical subunits.
3.2. Identi¢cation of the three non-identical subunits
constituting human DNase II
We have previously determined the N-terminal amino acid
sequence of the 32 kDa portion of human DNase II, up to the
30th residue [7]. However, the structures of the other compo-
nents remained to be determined. Edman degradation of the
8^10 kDa and 32 kDa components separated by SDS-PAGE
allowed the N-terminal amino acid sequences to be identi¢ed
up to the 39th and 37th residues, respectively (Fig. 2A). The
8^10 kDa component was initially predicted to be the L17^
D107 region of DNase II; however, its N-terminal sequence as
determined chemically was R47^S85, and this exactly matched
the sequence deduced from the cDNA data. Therefore, the
Q46^R47 bond of DNase II was demonstrated to be an addi-
tional cleavage site involved in proteolytic processing (Fig.
2B). In order to ascertain whether the L17^Q46 portion was
associated with the mature protein, the intact puri¢ed enzyme
was directly subjected to Edman degradation. Three di¡erent
phenylthiohydantoin-amino acid derivatives were detected
during each degradation cycle. These contained the N-termini
of the three components, two of which were identi¢ed as the
8^10 kDa and 32 kDa components. The N-terminus of the
other component was determined up to the 24th residue and
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Fig. 2. N-terminal amino acid sequences of the three non-identical subunits constituting mature DNase II (A) and the molecular organization
of the enzyme (B). A: The N-terminal amino acid sequences of each subunit are shown. Although the 5th residue of the propeptide may be
identical to the corresponding ones of the proprotein or mature protein, we assumed the 5th residue of the propeptide to be Gly, based on our
cDNA data. X indicates an undetermined position. B: The structural organization of human DNase II, as determined in this study, is shown.
The signal peptide (M1^A16), propeptide (L17^G46), proprotein (R47^D107) and mature protein (S108^I360) of the enzyme are indicated by open,
dotted, hatched and solid boxes, respectively. The numbering of the amino acid residues for each subunit is indicated below the corresponding
segment. The amino acid sequences surrounding putative processing sites are shown above or below each site and arrows designate the precise
processing site within the indicated sequence.
Table 2
Catalytic activities of DNase II deletion mutants expressed in COS-7 cells
Transfected construct DNase II activities (U104)
Cell lysates (units/Wg protein) Medium (units/Wl)
Control (non-transfected) 15.7 þ 3.50 3.68 þ 0.383
pcDNA-DN2 185 þ 38.1 43.5 þ 6.86
pcDNA-DN2anti 11.5 þ 2.65 3.71 þ 0.375
vSP 18.7 þ 0.975 3.33 þ 0.512
vPT 16.6 þ 7.17 3.84 þ 0.256
v(PT+P) 15.1 þ 4.36 3.69 þ 0.431
vM 17.6 þ 5.87 3.64 þ 0.358
v(P+M) 16.2 þ 5.41 3.96 þ 0.384
v(PT+M) 15.5 þ 3.45 3.46 þ 0.360
v(PT+P)/vM 53.3 þ 4.66 10.5 þ 0.383
v(PT+P)/v(PT+M) 16.2 þ 1.10 3.83 þ 0.371
vPT/v(P+M) 14.6 þ 3.88 3.18 þ 0.103
v(PT+P)/v(P+M)/v(PT+M) 14.0 þ 2.45 3.48 þ 0.151
pcDNA3.1(+) 14.7 þ 5.51 3.76 þ 0.384
A series of DNase II deletion mutants were constructed by using RT-PCR as described in the text. Cell lysates were prepared from COS-7 cells
transfected with the various mutants. These were assayed for DNase II and L-D-galactosidase activities and protein contents. The DNase II
activities of the culture media were also determined. Values are means þ S.D. of determinations for at least ¢ve transfections.
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corresponded to the L17^G40 portion of DNase II. These ¢nd-
ings show that mature DNase II is composed of three non-
identical subunits derived from a single DNase II precursor,
which is encoded by a single gene (Fig. 2B). Our experimental
results, obtained from a combination of cDNA and chemical
analyses, strongly indicate that mammalian DNase II exhibits
a three-chain structure formed by three non-identical polypep-
tides. In agreement with these results, during the preparation
of this article, porcine spleen DNase II was reported to consist
of three non-identical subunits [16].
3.3. Expression of human DNase II cDNA and its deletion
mutants in COS-7 cells
The entire coding region was cloned into a mammalian
expression vector (pcDNA3.1-DN2) and transiently expressed
in COS-7 cells (Table 2). The DNase II activities of both the
lysates and the culture medium from the transfected cells in-
creased 12-fold, compared with activity levels in non- and
mock-transfected cells containing endogenous DNase II,
whereas no signi¢cant enhancement of activity was observed
in the cells transfected with the antisense construct
(pcDNA3.1-DN2anti). These elevations in activity were com-
pletely abolished by the anti-human DNase II antibody. The
analyses of cDNA expression indicated that it encoded human
DNase II, and that the enzyme was in part diverted to the
secretory pathway. Some lysosomal enzymes are known to
exit the cell via the constitutive secretory pathway [17].
A series of deletion mutants derived from the human
DNase II cDNA were constructed and expressed in COS-7
cells (Table 2). To allow correct intracellular sorting and proc-
essing of lysosomal enzymes, these proteins would be expected
to need the signal peptide and potential N-glycosylation sites
in which the carbohydrate could be phosphorylated [17,18].
However, the cells transfected with the vS construct showed
no signi¢cant elevation of DNase II activity in their lysate or
culture medium. Therefore, the signal peptide was indispensa-
ble for the expression of intact DNase II, as well as other
lysosomal enzymes. None of the cells transfected with the
four deletion mutants v(PT+P), vM, v(P+M) or v(PT+M)
showed any increase in enzyme activity. These ¢ndings indi-
cate that the individual subunits (PT, P and M) exhibit no
catalytic activity. The propeptide regions of cathepsin L [19]
and L-hexosaminidase [20] have been reported to be essential
for the folding process. The cells transfected with the vPT
construct, as well as those transfected with the three sets of
constructs vPT/v(P+M), v(PT+P)/v(P+M)/v(PT+M) and
v(PT+P)/v(PT+M), showed no increase in the enzyme activity
of either their cell lysates or culture media. On the other hand,
the cells transfected with v(PT+P)/vM exhibited a signi¢cant
increase in activity which was completely abolished by the
antibody. When the e¡ect of the amount of vM cotransfected
with a constant amount of v(PT+P) on DNase II expression
was examined, activity increased in parallel with the amount
of vM. This increase occurred up to an approximately equiva-
lent molarity, then reached a plateau at high amounts, indi-
cating a stoichiometric association between these components
(data not shown). These ¢ndings suggest that, although a
single large DNase II precursor (PT+P+M) may not be nec-
essary for proteolytic maturation, the PT region L17^Q46 may
play an essential role in generating the active form of the
enzyme.
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